Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.

Abstract

Polymyxin B (PMB) and colistin, administered as the prodrug colistin methanesulfonate sodium (CMS), are increasingly used to treat carbapenem-resistant Gram-negative bacteria. Nephrotoxicity is the major dose-limiting adverse effect of both polymyxins. A retrospective cohort study of 132 patients was conducted to evaluate risk factors for acute kidney… (More)
DOI: 10.1016/j.ijantimicag.2013.12.002

Topics

  • Presentations referencing similar topics